The Joint Transnational Call (JTC) 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (acronym: CARMEN2026), co-funded by the European Union, will fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.